Latest Headlines

  1. AGC Biologics Lands Commercial Manufacturing Agreement For Yokohama Site Worth Hundreds Of Millions Of Dollars 7/28/2026

    Ahead of the official opening of AGC Biologics’ Yokohama site, an international biopharmaceutical company has already secured half of the facility’s mammalian manufacturing capacity with a multi-year commercial contract expected to reach hundreds of millions of dollars in total value. 

  2. New Carrying Straps Simplify Handling Of Meissner's 16 L CryoVault® Container 7/27/2026
  3. Kyverna Therapeutics And ElevateBio Enter Into Commercial Manufacturing And Supply Agreement For Miv-cel 7/27/2026

    Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19 directed CAR T-cell therapy.

  4. FUJIFILM Biosciences And NextCell Launch New Commercial Platform Comprised Of RUO Stromal Cells And Cell Culture Media 7/27/2026
  5. Rezon Bio Appoints Dr. Hubert Scholze As Chief Business Officer To Accelerate Global Commercial Expansion 7/20/2026
  6. Kindeva Appoints Brok Weichbrodt As Chief Transformation Officer To Accelerate Growth Strategy And Commercial Excellence 7/14/2026
  7. Cytovance Biologics Launches In-House Cell Line Development With High-Yield Titers Up To 10g/L 7/13/2026
  8. RoosterBio And Applied StemCell Partner To Advance Scalable iPSC-Based Bioprocess Solutions 7/8/2026

    Applied StemCell, Inc. ("ASC"), a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions.

  9. RoosterBio And Qkine Partner To Deliver A Single-Source Platform Of Cells, Media, And Growth Factors To U.S. Customers 7/7/2026

    RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins.

  10. Resilience Announces Relocation Of West Coast Headquarters To Ohio And Expansion Of Sterile Manufacturing Capabilities 7/1/2026